-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎WuXi AppTec Content Team Editor Merck & Co.
(MSD) recently announced that its anti-PD-1 therapy Keytruda, in combination with best supportive care (BSC), has been used in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib in Asia.
In patients, compared with placebo + BSC, patients' overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) were significantly improved
.
Liver cancer is one of the leading causes of cancer-related deaths worldwide
.
It is estimated that in 2020, there will be more than 905,000 new cases of liver cancer worldwide, and more than 830,000 people will die from the disease
.
An estimated 75% to 90% of primary liver cancer cases are hepatocellular carcinoma
.
Worldwide, the main factors that increase the risk of hepatocellular carcinoma are chronic hepatitis B and C, alcohol consumption, and metabolic syndrome
.
Keytruda is an anti-PD-1 monoclonal antibody therapy that blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2, thereby activating T lymphocytes
.
Merck currently has more than 1,600 trials investigating the efficacy of Keytruda in a variety of cancers and treatment settings
.
The randomized, double-blind, placebo-controlled Phase 3 clinical trial, called KEYNOTE-394, was conducted in Asian patients
.
They had advanced hepatocellular carcinoma and had been treated with sorafenib or oxaliplatin-based chemotherapy
.
The trial results showed that Keytruda+BSC reduced the risk of death by 21% compared with placebo+BSC (HR=0.
79, 95% CI, 0.
63-0.
99; p=0.
0180)
.
Median OS was 14.
6 months (95% CI, 12.
6-18.
0) for patients treated with Keytruda+BSC compared with 13.
0 months (95% CI, 10.
5-15.
1) for patients treated with placebo+BSC
.
In addition, Keytruda+BSC reduced the risk of disease progression or death by 26% (HR=0.
74, p=0.
0032)
.
The ORR was 12.
7% in the Keytruda+BSC arm and 1.
3% in the placebo+BSC arm
.
In terms of safety, treatment-related adverse events (TRAEs) occurred in 66.
9% of patients in the Keytruda+BSC group and 49.
7% of the patients in the placebo+BSC group, and 14.
4% of the patients in the Keytruda+BSC group and 5.
9% of the patients in the placebo+BSC group.
The patient developed grade 3-5 TRAE, please refer to reference [1] for detailed data
.
"Patients with advanced hepatocellular carcinoma continue to have a high unmet medical need and poor survival," said Dr.
Scot Ebbinghaus, vice president of clinical research at Merck Laboratories
.
"
We are pleased to share these new data from KEYNOTE-394 and are An extensive global hepatocellular carcinoma R&D program advances research in patients with this difficult-to-treat cancer
.
"Reference: [1] Merck's KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo in Certain Patients With Advanced Hepatocellular Carcinoma (HCC) Previously Treated With Sorafenib.
Retrieved January 19, 2022, from https://www.
merck.
com/news/mercks-keytruda-pembrolizumab-significantly-improved-overall-survival-os-versus-placebo-in-certain-patients-with-advanced-hepatocellular-carcinoma-hcc-previously-treated-with-sora/ Disclaimer: The WuXi AppTec content team focuses on introducing the progress of global biomedical health research
.
This article is for information exchange purposes only.
The views in this article do not represent WuXi AppTec's position, nor do they support or oppose the views in the article
.
This article is not a treatment Program recommendation
.
If you need treatment program guidance, please go to a regular hospital for treatment
.